Skip to content
DomDNA LAB

Research library · Genomics

Penetrance and expressivity answer different questions

DomDNA editorial resources · Released · Research 2026-10-04 · 4 min read

Draft • Research checked 4 October 2026 • AI-assisted DomDNA editorial content. No independent clinical review or publication is claimed. General education, not individual medical advice.

You read that a genetic condition has incomplete penetrance and variable expressivity. The terms describe two kinds of variation: how many people with a particular genetic change show the condition, and how the condition appears among people who have it.

Your reader question is: “Does this number describe who develops features, or does it describe how those features vary?” Keeping the distinction helps you ask a clear question about a report without treating a group estimate as a prediction of your future.

Count the outcome before describing it

MedlinePlus explains reduced penetrance as some people with a relevant genetic variant developing features of a disorder while others do not. It describes variable expressivity as differences in features among affected people. Genetic, environmental and other factors can contribute; researchers may not know the full explanation.

Picture an invented study of 100 adults who share a particular change. By the study’s chosen age, researchers identify the defined condition in 60 participants. The illustrative penetrance at that age is 60%. We invented the change, condition and counts. They provide no estimate for any known gene or person.

Now imagine that the researchers record mild features in some of those 60 participants and more severe features in others. They are describing variation in expression among affected participants. “60% penetrance” does not mean that an affected person has 60% of the condition or that symptoms will reach 60% of their possible severity.

Keep age and the definition beside the percentage

NHS England’s penetrance explainer describes penetrance as a proportion determined through population studies. To understand a reported estimate, ask who the researchers studied and how they decided whether someone had the phenotype, meaning the observable features.

In the fictional study, “by the chosen age” belongs beside “60%”. A reader would need additional observations to say what happens later. Someone who has no defined features at one assessment has not supplied a lifetime observation.

The researchers’ outcome definition also matters. If one study counts a measured sign and another counts a diagnosed condition, you need to know that before comparing the percentages. Preserve the paper’s definition instead of replacing it with a broad phrase such as “gets ill”.

Describe the differences without ranking the person

The NHS expressivity explainer describes differences in presentation and severity. It also notes that the reasons can remain unknown. A shared genetic change does not supply a complete description of someone’s needs or experience.

You can record the features a study examined without turning them into a judgement about which person is “more genetic”. In the invented example, a researcher might assess two signs with a defined scale. The scale describes those signs under that method. It does not summarise someone’s whole health or predict their treatment.

Avoid importing another person’s experience into your own report. A similar diagnosis or a shared variant can still leave differences that require clinical explanation. If you need advice about your health, bring the complete report and your question to a qualified clinician or genetic counsellor.

Use an explanation that preserves both uncertainties

NHS England’s communication aid separates the proportion who show a condition from the different ways it can affect them. It notes that variation can occur within a family as well as between unrelated people. It supports a conversation; it does not calculate an individual prognosis.

For your notes, write one line for the estimate’s population and age, and another for the range of features described. Add the report’s exact wording. This prepares a question without deciding whether an unexplained symptom belongs to a genetic condition.

Your next step is to ask the testing team which of these two concepts a statement in your report describes. DomDNA’s educational quiz covers general lifestyle topics. It does not estimate penetrance, assess expressivity or diagnose conditions.

Original source and access ledger

  1. MedlinePlus penetrance and expressivity

    sourceDate: 2021-04-19

    type: Government genetics education, last updated 2021-04-19

    population: People learning about genetic conditions

    endpoint: Proportion affected and variation among affected people

    supportedClaimAndLimit: Defines both concepts; contributing factors can remain unresolved, no individual prognosis.

    fundingAndConflicts: Official educational or technical documentation; no product endorsement inferred.

    accessEvidence: Relevant source text opened via web on 2026-10-04; no personal health data transmitted.

    researchDate: 2026-10-04

    correctionStatus: Access-date source check only; no comprehensive correction, retraction or guideline-surveillance audit claimed.

  2. NHS penetrance explanation

    sourceDate: Revision date not established; accessed 2026-10-04

    type: Official clinical-education resource

    population: People with a relevant genotype in population studies

    endpoint: Proportion showing a defined phenotype

    supportedClaimAndLimit: Population estimates require defined participants and features; no borrowed gene-specific risk numbers.

    fundingAndConflicts: Official educational or technical documentation; no product endorsement inferred.

    accessEvidence: Relevant source text opened via web on 2026-10-04; no personal health data transmitted.

    researchDate: 2026-10-04

    correctionStatus: Access-date source check only; no comprehensive correction, retraction or guideline-surveillance audit claimed.

  3. NHS expressivity explanation

    sourceDate: 2025-04-14

    type: Official clinical education, reviewed 2025-04-14

    population: People with genetic conditions

    endpoint: Variation in presentation and severity

    supportedClaimAndLimit: Features can differ among affected people; causes of variation may remain unknown.

    fundingAndConflicts: Official educational or technical documentation; no product endorsement inferred.

    accessEvidence: Relevant source text opened via web on 2026-10-04; no personal health data transmitted.

    researchDate: 2026-10-04

    correctionStatus: Access-date source check only; no comprehensive correction, retraction or guideline-surveillance audit claimed.

  4. NHS penetrance and expressivity communication aid

    sourceDate: 2025-06-17

    type: Official patient-communication aid, reviewed 2025-06-17

    population: Patients discussing genetic conditions with clinicians

    endpoint: Explaining reduced penetrance and variable expressivity

    supportedClaimAndLimit: Aid distinguishes occurrence from presentation including within a family; not a prognosis calculator.

    fundingAndConflicts: Official educational or technical documentation; no product endorsement inferred.

    accessEvidence: Relevant source text opened via web on 2026-10-04; no personal health data transmitted.

    researchDate: 2026-10-04

    correctionStatus: Access-date source check only; no comprehensive correction, retraction or guideline-surveillance audit claimed.

Download exact original article Markdown · Download exact source and unsent social pack

Finished companion media

Silent films, slides and source captions on the separate dashboard. Original preview and historical product limits remain in their captions. No social campaign has been sent.